Swedish Orphan Biovitrum Ab (($GB:0MTD)) announced an update on their ongoing clinical study. IQVIA Holdings and Swedish ...

Apellis Pharmaceuticals (($APLS)) announced an update on their ongoing clinical study. Apellis Pharmaceuticals is conducting a study titled An ...

In sum, Novartis accused Alexion of launching “a false and misleading marketing campaign that is unsupported by scientific ...

Older AA/PNH patients who have myeloid driver mutations at baseline and a poor response to nontransplant treatment have a higher risk of progression to sMN. Baseline-prevalent mutations (PIGA/human ...

Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

Ilene Weitz, MD, details a few abstracts on paroxysmal nocturnal hemoglobinuria (PNH) treatments that will be presented at ASH 2024, particularly data on danicopan as an add-on to ravulizumab or ...

A retrospective analysis suggested that immune cells play a role in the progression of paroxysmal nocturnal hemoglobinuria (PNH). Furthermore, as Daria Babushok, Division of Hematology-Oncology, ...

Novo Nordisk will now run a Phase III trial for Omeros' former lead asset, zaltenibart in rare blood disorder, PNH.

Apellis Pharmaceuticals is taking a victory lap. Less than two weeks after the FDA approved Apellis’ C3 inhibitor pegcetacoplan, marketed as Empaveli, for patients with a rare blood disorder known as ...

Eculizumab was the first-in-class complement C5 inhibitor for PNH. Can you elaborate on the mechanism of action of eculizumab and its impact on the management of PNH? Please elaborate on the ...

Pregnancy exacerbates PNH-related manifestations. Complement inhibition has improved both maternal and fetal outcomes. Most hematologists agree that the benefits of complement inhibition during ...